Newsroom

March 2017

• 
  Story Mar 29, 2017 From Our Labs

  Could digital technology drive clinical research in Africa?

  Novel digital platform for clinical trial data collection could help facilitate much-needed biomedical research in lower-income countries.

• 
  Story Mar 28, 2017 Discovery

  Eyewitness to a healer pursues new treatments for patients

  Inspired by her mother, Vicky Qi leads drug discovery teams.

• Press release Mar 23, 2017

  Alcon receives US FDA approval for new AcrySof® IQ ReSTOR® +2.5 Multifocal Toric IOL with ACTIVEFOCUS(TM) design for uncompromised distance vision and presbyopia correction

  The unique optical design of the ACTIVEFOCUS(TM) toric IOL gives astigmatic cataract patients quality distance vision and an increased range of vision to potentially reduce dependence on glasses…
• 
  Story Mar 22, 2017 Discovery

  Striving to vanquish leukemia

  Combination of two compounds shows promise in the lab

• Press release Mar 22, 2017

  Novartis provides update on Phase III study of RLX030 (serelaxin) in patients with acute heart failure

  Phase III RELAX-AHF-2 study did not meet primary endpoints of reduced cardiovascular death or worsening heart failure in patients with acute heart failure  Novartis remains committed to…
• Press release Mar 21, 2017

  Novartis' Cosentyx is first and only IL-17A inhibitor to potentially modify the course of psoriasis

  New data suggests that disease modification with Cosentyx may be achievable for around 20% of patients following one year of treatment[1]  Patients with longer disease duration before…
• Press release Mar 18, 2017

  New analysis shows Novartis Entresto improves glycemic control in reduced ejection fraction heart failure patients with diabetes

  New post-hoc analysis of PARADIGM-HF data demonstrates Entresto lowered levels of HbA1c (a measure of glycemic control) by 0.26% vs. 0.16% for ACE-inhibitor enalapril in heart failure with reduced…
• Press release Mar 13, 2017

  Novartis Kisqali® (ribociclib, LEE011) receives FDA approval as first-line treatment for HR+/HER2- metastatic breast cancer in combination with any aromatase inhibitor

  Approved based on a first-line Phase III trial that met its primary endpoint of progression-free survival (PFS) at interim analysis due to superior efficacy compared to letrozole alone[1] …
• Press release Mar 13, 2017

  Sandoz announces winners of inaugural Healthcare Access Challenge (Sandoz HACk)

  Three winners, chosen by expert panel at Wired Health 2017 in London, identified innovative approaches to address access challenges in Ghana, the Maldives and the Philippines. Winning ideas…
• Press release Mar 06, 2017

  Novartis' Cosentyx shows almost all psoriasis patients rapidly regain skin clearance following a treatment pause

  New analysis shows 94% of patients on Cosentyx® regained PASI 75, with up to 80% of patients regaining PASI 90 to 100 after only 16 weeks of retreatment[1]  Cosentyx has shown superior and…
• Press release Mar 06, 2017

  New data demonstrate Sandoz proposed biosimilar adalimumab has equivalent efficacy to reference medicine

  Sandoz proposed biosimilar adalimumab (GP2017) shown to have equivalent efficacy and a similar safety profile as reference medicine, Humira®*Comprehensive development program show potential of GP2017…
• 
  Story Mar 06, 2017 Patient Perspectives

  Inside a cancer diagnosis

  Melanoma survivor T.J. Sharpe shares key insights about the cancer diagnosis experience.